Nanobiotix SA is a pioneering clinical-stage biotechnology company based in Paris, France, dedicated to advancing innovative cancer treatments through its proprietary nanotechnology platform. The company specializes in the development of localized therapies aimed at enhancing the efficacy of existing cancer treatments while minimizing adverse effects. With a robust portfolio of candidates in various stages of clinical trials, Nanobiotix is positioned at the forefront of cancer care innovation, leveraging its unique approach to improve patient outcomes in oncology. As it continues to explore strategic partnerships and collaborations, the company aims to redefine cancer treatment paradigms and provide novel solutions for patients worldwide.